475 related articles for article (PubMed ID: 30806788)
1. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
2. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
3. Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.
Yuan H; Chen J; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Clin Cancer Res; 2015 Oct; 21(19):4365-72. PubMed ID: 25979484
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
5.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
7. Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer.
Jiang YZ; Yu KD; Bao J; Peng WT; Shao ZM
Cancer Res; 2014 Jul; 74(13):3399-407. PubMed ID: 24924774
[TBL] [Abstract][Full Text] [Related]
8. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Loi S; Michiels S; Lambrechts D; Fumagalli D; Claes B; Kellokumpu-Lehtinen PL; Bono P; Kataja V; Piccart MJ; Joensuu H; Sotiriou C
J Natl Cancer Inst; 2013 Jul; 105(13):960-7. PubMed ID: 23739063
[TBL] [Abstract][Full Text] [Related]
10. TP53 mutations are associated with higher rates of pathologic complete response to anthracycline/cyclophosphamide-based neoadjuvant chemotherapy in operable primary breast cancer.
Wang Y; Xu Y; Chen J; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2016 Jan; 138(2):489-96. PubMed ID: 26238069
[TBL] [Abstract][Full Text] [Related]
11. Relapsed and De Novo Metastatic HER2-positive Breast Cancer Treated With Trastuzumab: Tumor Genotypes and Clinical Measures Associated With Patient Outcome.
Kotoula V; Tsakiri K; Koliou GA; Lazaridis G; Papadopoulou K; Giannoulatou E; Tikas I; Christodoulou C; Chatzopoulos K; Bobos M; Pentheroudakis G; Tsolaki E; Batistatou A; Kotsakis A; Koutras A; Linardou H; Razis E; Res E; Pectasides D; Fountzilas G
Clin Breast Cancer; 2019 Apr; 19(2):113-125.e4. PubMed ID: 30545790
[TBL] [Abstract][Full Text] [Related]
12. Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
Park JH; Ahn JH; Kim JE; Jung KH; Gong G; Lee HJ; Son BH; Ahn SH; Kim HH; Shin HJ; Moon DH; Kim D; Kim SB
Anticancer Res; 2020 Oct; 40(10):5883-5893. PubMed ID: 32988919
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Moon WK; Chen HH; Shin SU; Han W; Chang RF
Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
[TBL] [Abstract][Full Text] [Related]
14. Surgical resection of breast cancers: Molecular analysis of cancer stem cells in residual disease.
Pommier SJ; Morgan RE; Limbach KE; Jackson CM; Naik AM; Peckham JL; Muller PJ; Condron ME; Jameson NE; Pommier RF
Surgery; 2019 May; 165(5):1008-1013. PubMed ID: 30777364
[TBL] [Abstract][Full Text] [Related]
15. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
16. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
18. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
19. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer.
Sheng S; Xu Y; Guo Y; Yao L; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Int J Cancer; 2020 Jan; 146(2):487-495. PubMed ID: 31119730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
